Championing the mission to become the premier digital publisher, Retail Investor 360 seeks to empower readers with related news, intelligence, education and proprietary market research. While focusing on biopharmaceutical analysis and consultation, we also provide 360 coverage on a plethora of companies in other industries. Under the guidance and ownership of Vincata Enterprises LLC, we strive for highest corporate compliance and responsibility.
Our authors are experts, who possess complimentary skills and employ the middle-ground approach toward investing research. As scientists, physicians and analysts, our expertise span beyond financial valuations. We are highly knowledgeable of the mechanism of action of various molecules, physicians' prescribing pattern and other market factors, which positioned us to assist both biopharmaceutical firms and investors.
We are relatively new and are undergoing changes. Do not hesitate to contact us if you have feedbacks. Your inputs are truly appreciated.
The following are information for Dr. Hung V. Tran, Chief Medical Analyst and Consultant:
I founded Retail Investor 360 and Vincata Enterprises LLC in 2013 to help everyday investors invest prudently as well as to assist life science firms gain exposure to the investing community. The ultimate results are two prongs: more lifesaving medicine for patients and market intelligence for investors.
My diverse background as an independent financial analyst, medical doctor, entrepreneur and chemistry instructor complements the integrated investing research that I pioneered.
The first rule of integrated investing is to realized one’s limitation. For instance, physicians who are rigidly scientific tend to lack the analytical prowess of financial experts. Conversely, financiers typically do not possess the medical expertise of healthcare providers. Likewise, scientists are skillful in data analysis but they may not be familiar with prescribing patterns.
The second rule is to move beyond one’s circles of competence through learning various disciplines as well as leveraging on others’ expertise. In doing so, I tap into the the intelligence of physicians, financiers and scientists in my network.
The third rule is to seek intelligence not available in the balance sheet via conducting field research. Accordingly, I gained much insight through informal patient as well as consumer surveys. If needed, I run my own statistical tests.
All that being said, integrated investing research helped me to accurately forecast the outcomes of numerous clinical trials like the Flint of Intercept, Ascend of InterMune and Affinity of MannKind, far in advance of the market.
Despite my focus on the life science sector, I cover other industries from time to time. And my work has expanded to assisting not only retail investors but professionals as well. I mostly publish long investing theses, as the rewards are most substantial. Nonetheless, I issue short theses once in a blue moon. This is not to short firms but to sharpen the skills needed to lead readers away from cautious investing.
Interestingly, my overall accuracy in the short thesis has been far better than the long counterparts. It is imperative for the readers to realize that one does not need to achieve 100 percent accurate results. The keys are to maintain this above average accuracy and to have adequate portfolio diversification. As long as you are right six out of ten times, you should achieve market outperformance in the long run.
Please note that I am not a registered investment advisor. Even if I am, you still need to consult with your own financial advisor, as your circumstance can be different from someone else’s. My research are not recommendations to buy, sell or transact any forms of security. And though I strive to provide the most accurate information available, the nature of information changes over time. Therefore, I can neither guarantee the accuracy nor timeliness of such information that, in and of themselves, are presented “as is.” You should use my articles as educational and informational materials to help you in your own due diligence.
I also write for Seeking Alpha from time to time. You can check out my articles at http://seekingalpha.com/author/md-research/articles#regular_article
less
